Oncology Central

Toward improved effectiveness of bladder cancer immunotherapy


Urothelial cancer (bladder cancer; BCa) accounts for over 70,000 new cases and 15,000 deaths annually in USA. Although it can be successfully treated in its early stages, it has extremely high recurrence rates and becomes increasingly resistant to treatment at later stages. Intravesical BCG treatment reduces the recurrence rates of BCa from 60–70% to 30–40% and it is considered a prototypical target of cancer immunotherapy [1–3]. However, low overall durability of BCG responses beyond 2–3 years and the significant risk of progression to muscle invasive disease in spite of initial responses resulted in attempts to improve time to recurrence through BCG maintenance strategies [4].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.